S.A.L.A.R.S.

Salars, LLC was a biotechnology company focused on the development of the Surface-Active Liposome-Associated Receptor System (SALARS), a proprietary drug delivery platform. The company's technology utilized pH-sensitive and receptor-targeted liposomes designed to deliver therapeutic agents directly to diseased cells while minimizing systemic toxicity. By engineering nanocarriers that respond to the specific microenvironment of tumors or inflammatory sites, Salars aimed to enhance the precision and efficacy of existing drugs like doxorubicin and paclitaxel. The company operated as an early-stage R&D entity, primarily advancing its pipeline through pre-clinical studies and academic collaborations. Although the company is no longer active, its foundational work in stimulus-responsive drug delivery remains a significant contribution to the field of nanomedicine.